Sermorelin
A GHRH analogue used to diagnose and treat poor growth in children and anti-aging in adults.
Common Dosage
100mcg - 300mcg daily at night
Category
Anti-Aging
- Natural GH release
- Sleep quality
- Body composition
Sermorelin (GHRH 1-29 NH2) is a synthetic version of the first 29 amino acids of endogenous GHRH — the shortest fragment retaining full biological activity. It was FDA-approved (as Geref) for treatment of growth hormone deficiency in children. Though Geref was later discontinued due to commercial reasons (replaced by recombinant GH), sermorelin has remained widely used in anti-aging and functional medicine as a safer, more physiological alternative to direct growth hormone injection. It is the most well-established GHRH analogue in clinical anti-aging practice.
Sermorelin binds to GHRH receptors on pituitary somatotrophs, stimulating GH synthesis and release in a pulsatile, feedback-regulated pattern. Unlike exogenous GH, sermorelin preserves hypothalamic-pituitary-axis feedback mechanisms — the pituitary continues to respond appropriately to somatostatin suppression. This means sermorelin stimulates GH release only when physiologically appropriate, reducing the risk of supraphysiological IGF-1 elevation seen with direct GH therapy.
- Pediatric growth hormone deficiency — former FDA indication
- Age-related GH decline (somatopause) — anti-aging medicine
- Body composition improvement in older adults
- Sleep quality enhancement
- Bone mineral density support
- Metabolic health optimization
Anti-Aging Practice Outcomes
Anti-aging practitioners using sermorelin as first-line GH optimization therapy report consistent improvements in patient-reported outcomes including sleep quality, energy, body composition (reduced fat, preserved muscle), and skin quality over 3–6 month courses. IGF-1 elevations are typically physiological rather than supraphysiological — a key safety advantage.
Bone Density in Aging Adults
Studies on GH-deficient adults receiving GHRH analogues including sermorelin have shown improved bone mineral density markers — consistent with GH's role in calcium retention and bone remodeling. This application is increasingly relevant as an adjunct to osteopenia management.
- Flushing at the injection site and face are common
- Pituitary desensitization with continuous non-cycled use
- IGF-1 monitoring recommended, particularly in older individuals with elevated cancer risk
- Half-life is very short (~11 minutes) — timing of injection is important for effect
- FDA approval was for pediatric use only — adult anti-aging use is off-label
- Flushing
- Injection site reaction